High-Content Analysis Market Outlook

By Richard Fisler, Beachhead Consulting, and Jocelyn Burke, Ph.D. 

High-Content Analysis Market Outlook is a new Cambridge Healthtech report that quantifies the current and future market size for high-content analysis (HCA) systems, software, and reagents. Key areas of implementation and growth potential, as well as areas of future development that will also impact the overall market size, are identified and analyzed. 

HCA technologies try to massively parallelize analyses currently done one at a time on a microscope or other equipment designed to measure intracellular events. Emerging tools and capabilities in HCA are driving a wave of new opportunities for investment on both the supply and demand sides as new hardware systems, software applications, and reagent kits are enabling researchers to study intracellular events on hundreds of thousands of cells a month. 

The data used for High-Content Analysis Market Outlook is based on in-depth interviews with end-users in the pharmaceutical industry and the vendor community. More than 20 interviews were conducted to gain an understanding of both the current applications of HCA technologies and the desired applications. Strong attention was paid to current limitations in technology that hinder widespread adoption as well as budgetary concerns by the end users that may limit their ability to invest in new technologies.  

The report presents a detailed financial model for the HCA market. Because HCA is a new technology and a new market, the model is based on the adoption curves of similar technologies and focuses on the application areas of highest potential. Most assumptions are listed for a more complete understanding of the model and how it was constructed.

Gain New Insight into the HCA Market:   

> An overview of the current state of cell- based assays in drug development and the numerous opportunities that exist to increase the quality of screens using high content analysis.

> A profile of the HCA customer and an analysis of factors influencing the adoption of HCA technology.

> A five-year projection of spending on new equipment and reagents.

> Impact of HCA on systems biology.  

About the Authors

Richard Fisler is a consultant with Beachhead consulting (www.beachhead.com), a consulting firm specializing in technology evaluation, strategic planning, and market assessment in the life science industry. Prior to his work at Beachhead, he brought a wide variety of high technology platforms to market through positions in the microarray and live cell microscopy industries. Additionally, he has spent 11 years in management and engineering in the medical imaging field. 

Jocelyn Burke, Ph.D., Consulting Executive, guides venture capitalists and biotech companies through mission creation, strategy formulation, and new product development. While formerly Vice President and General Manager at Packard BioScience Co., Dr. Burke developed and commercialized numerous new products including instrumentation, software, robotic liquid handling, reagents, and assay platforms for high-throughput screening, tissue imaging, and protein biochip array creation and detection.  

Report #36

Published in March 2004 by Cambridge Healthtech, 36 pages.

Publisher: Cambridge Healthtech Advisors 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Cambridge_Healthtech_Advisors.html#a500